Purpose: Methamphetamine is a powerful, highly addictive stimulant which affects the central nervous system. Therefore, this study was aimed at evaluating the efficacy of modafinil in the treatment of patients with MA dependence.Methods: A randomized parallel controlled trial study was designed to compare the effectiveness of take-home, self-administered modafinil treatment in the intervention group and the controlled group in three months. The primary outcome measurements were severity and duration of craving, and selfreported methamphetamine consumption, as confirmed by urine drug test.Results: The relapse rate was 40 and 75 % in the intervention and controlled groups, respectively, indicating a decrease in relapse rate of MA in the intervention group (p < 0.05). During the three months, the severity and the duration of drug abuse craving in the intervention group were less than in the controlled group. Patients in the intervention group experienced an increase in retention rate and a decrease in slip rate (p < 0.05)Conclusion: The use of modafinil is not only effective on craving and relapse reduction, but also changes urine drug screens of patients with MA dependence to negative. Thus, modafinil is safely indicated as an effective medication to reduce withdrawal symptoms and the craving of patients with MA dependence